HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Methylnaltrexone Has No Significant CNS Activity in Patients with OIC

Subcutaneous methylnaltrexone does not affect pain intensity or analgesic use in patients with chronic nonmalignant pain and opioid-induced constipation, according to findings from a study presented at the American Pain Society's annual conference.

Subcutaneous methylnaltrexone does not affect pain intensity or analgesic use in patients with chronic nonmalignant pain and opioid-induced constipation, according to findings from a study presented at the American Pain Society’s 29th Annual Scientific Meeting.

In the study, which was led by Arnold J. Weil, MD, of Non-Surgical Orthopedics, Atlanta, GA, patients taking opioids daily for chronic nonmalignant pain received methylnaltrexone 12 mg once daily, methylnaltrexone 12 mg every other day, or placebo for 4 weeks. Use of routine laxatives was not permitted; however, rescue laxatives were allowed, if needed, after 3 days without laxation, according to a report published in Monthly Prescribing Reference.

Patients were included if they had chronic pain due to a nonmalignant underlying condition for at least two months and were taking a daily dose of ≥50 mg oral morphine equivalents for ≥2 weeks. Opioid-induced constipation during screening was defined as ≤2 rescue-free bowel movements per week associated with at least one of the following: hard or lumpy stools, straining during bowel movements, or sensation of incomplete evacuation after bowel movement.

Using an 11-point Pain Intensity Scale (scale 0-10), researchers measured pain intensity at baseline and on study days 14 and 28, and opioid use was measured in daily oral morphine equivalents.

Of the 460 patients who were randomized and received at least one dose of study medication, 388 completed the study, with 122 in the methylnaltrexone once daily dose group, 120 in the methylnaltrexone every other day dose group, and 146 in the placebo group. Mean age was similar among the treatment groups: 48.0 years in the methylnaltrexone once daily group, 48.6 years in the methylnaltrexone every other day dose group; and 49.7 years in the placebo group. Approximately two thirds of the patients in each group were female and most were white. Back pain was the primary pain condition in each group; others included cervical/neck pain, fibromyalgia, osteoarthritis, and low extremity/hip pain.

Compared with baseline, no treatment differences were observed in pain-scale changes. At day 14, mean pain scores were 6.2 for the methylnaltrexone 12 mg/day dose, 6.1 for alternate-day dosing, and 6.2 for placebo; at day 28, the adjusted mean scores were 6.1, 5.9, and 6.3, respectively. Adjusted mean changes in pain scores from baseline were similar in all treatment groups: at day 14, those changes were -0.1, -0.1, and 0; at day 28, they were -0.2, -0.3, and -0.1. No significant differences in median daily opioid use were found during the double-blind period for either treatment group compared with placebo.

These results suggest absence of significant methylnaltrexone activity in the central nervous system, said investigators.